Cilansetron

Drug Profile

Cilansetron

Alternative Names: KC 9946

Latest Information Update: 03 Mar 2010

Price : $50

At a glance

  • Originator Solvay Pharmaceuticals
  • Class Irritable bowel syndrome therapies
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Irritable bowel syndrome

Most Recent Events

  • 11 Jul 2007 No development reported - Phase-III for Irritable bowel syndrome in Europe (PO)
  • 11 Jul 2007 No development reported - Phase-III for Irritable bowel syndrome in United Kingdom (PO)
  • 29 Nov 2005 Suspended - Preregistration for Irritable bowel syndrome in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top